Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pulmicort Clear all
Not listed No phase listed Observational

Evaluating Adrenal Insufficiency in Adults With Eosinophilic Esophagitis on Chronic Swallowed Topical Steroids

NCT05246085
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cortisol level
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD

NCT06075095
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
19
States / cities
Sheffield, Alabama • Clearwater, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 13, 2026, 2:28 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT07358234
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], budesonide oral suspension
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 13, 2026, 2:28 PM EDT
Not yet recruiting Phase 4 Interventional

Fasenra: An Asthma Study

NCT07654842
View directory record Official record
Conditions
Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Interventions
Budesonide-albuterol, Benralizumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 13, 2026, 2:28 PM EDT
Withdrawn Not applicable Interventional

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

NCT00388739
View directory record Official record
Conditions
Asthma
Interventions
Intervention: Budesonide, Usual care: albuterol + systemic steroids
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Sep 13, 2026, 2:28 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

NCT00217022
View directory record Official record
Conditions
Lymphocytic Colitis, Diarrhea
Interventions
Placebo, Budesonide
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 13, 2026, 2:28 PM EDT
Withdrawn Phase 2 Interventional

Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery

NCT01814618
View directory record Official record
Conditions
Olfaction Disorders, Sinusitis, Paranasal Sinus Diseases
Interventions
Budesonide Respules
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 84 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 13, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease

NCT02123966
View directory record Official record
Conditions
Chronic Graft-versus-Host-Disease, Oral Mucosal Disease Due to Graft-versus-host Disease
Interventions
Sirolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 13, 2026, 2:28 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients

NCT03303677
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Saline Nasal, Budesonide Nasal, Topical Antibacterial (Product)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Sep 13, 2026, 2:28 PM EDT
Withdrawn Phase 2 Interventional

Coronavirus Smell Therapy for Anosmia Recovery

NCT04422275
View directory record Official record
Conditions
Anosmia
Interventions
Budesonide, High-Concentration Essential Oil, Placebo, Low-Concentration Essential Oil
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

NCT02727660
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disorder
Interventions
BFF MDI (PT009) 320/9.6 μg, BFF MDI (PT009) 160/9.6 μg, FF MDI (PT005) 9.6 μg
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
121
States / cities
Dothan, Alabama • Huntsville, Alabama • Sheffield, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 13, 2026, 2:28 PM EDT
Not listed Phase 4 Interventional

A Pilot Study Involving an Asthma Management Program for Inner-city Early Head Start Children

NCT00624429
View directory record Official record
Conditions
Asthma
Interventions
Budesonide respules
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
12 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2009 · Synced Sep 13, 2026, 2:28 PM EDT
Terminated Phase 3 Interventional Results available

ARrest RESpiraTory Failure From PNEUMONIA

NCT04193878
View directory record Official record
Conditions
Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Interventions
Inhaled budesonide and formoterol, Inhaled placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy

NCT02069847
View directory record Official record
Conditions
Esophageal Stricture
Interventions
Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Steroid Nasal Irrigation for Flavor Evaluation and Detection Study

NCT02985515
View directory record Official record
Conditions
Olfactory Disorder
Interventions
Smell training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 13, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

NCT00805285
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Combination Oral Budesonide and Rectal Hydrocortisone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 13, 2026, 2:28 PM EDT
Not listed Phase 2 Interventional

Pilot Study of Topical Steroid for Prevention of Chronic Lung Disease in Extremely Premature Infants.

NCT01268215
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Infasurf, Pulmicort, Sham
Drug · Other
Lead sponsor
East Carolina University
Other
Eligibility
24 Weeks to 28 Weeks
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

NCT04609878
View directory record Official record
Conditions
Asthma
Interventions
BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
2,274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
107
States / cities
Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
View directory record Official record
Conditions
Asthma
Interventions
BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Sep 13, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient

NCT05322707
View directory record Official record
Conditions
Asthma
Interventions
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, Placebo
Drug
Lead sponsor
Cipla Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 13, 2026, 2:28 PM EDT